Trials / Completed
CompletedNCT00487747
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
PEGASYS® (Peginterferon Alpha-2a 40KD) in Patients With HBeAg-positive and HBeAg-negative Chronic Hepatitis B
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This single arm study will assess the efficacy and safety of PEGASYS in patients with chronic hepatitis B who are either treatment-naive, or who have failed lamivudine- or interferon-treatment in the past. All patients will receive PEGASYS, 180 micrograms s.c. weekly for 48 weeks, followed by 48 weeks of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | peginterferon alfa-2a [Pegasys] | 180 micrograms sc weekly for 48 weeks |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2007-06-19
- Last updated
- 2017-04-06
- Results posted
- 2017-04-06
Locations
23 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT00487747. Inclusion in this directory is not an endorsement.